CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Fluoxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02017535
NCT02017535Phase 2Completed
CompareCT.gov

A Personalized Approach to Achieving a Sustained Response to Treatment for Adolescent Depression

University of Minnesota·interventional·Posted Dec 20, 2013·Updated Mar 23, 2020

In Brief

A Phase 2 clinical trial evaluating Fluoxetine and Interpersonal Psychotherapy for Adolescent Depression. Completed, enrolled 15 participants across 1 site.

Detailed Summary

Aim 1: Assess the feasibility and acceptability of the personalized continuation treatment strategy. Aim 2: Estimate variances of primary and secondary outcomes with the continuation treatment. Aim 3: Conduct exploratory hypothesis-generating analyses to inform further development of the personalized continuation treatment strategy to be tested in a subsequent R01 proposal.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdolescent Depression
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 20, 2013
Enrollment StartJun 1, 2012
Primary CompletionOct 1, 2018
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 12.5 years ago

Interventions

Fluoxetinedrug

Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.

Interpersonal Psychotherapybehavioral

Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.